Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired AnaptysBio, Inc. (“AnaptysBio”) (NASDAQ: ANAB) common stock between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made false and misleading statements regarding the purported efficacy of etokimab, AnaptysBio’s targeted treatment for inflammatory diseases, touting data from the company's Phase 2a trial in peanut allergies as showing a "remarkable efficacy result" and describing the drug as having a "pretty profound efficacy" in its treatment of patients with atopic dermatitis. Specifically, the complaint alleges that Defendants provided misleading clinical trial data which failed to disclose key information and used questionable analysis, making the trial results regarding etokimab's efficacy and its prospects appear far better than they were.
Current Status of Case:
On November 30, 2021, the Court granted the Motion to Dismiss. This action has concluded.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.